JP4384918B2 - ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 - Google Patents
ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 Download PDFInfo
- Publication number
- JP4384918B2 JP4384918B2 JP2003585719A JP2003585719A JP4384918B2 JP 4384918 B2 JP4384918 B2 JP 4384918B2 JP 2003585719 A JP2003585719 A JP 2003585719A JP 2003585719 A JP2003585719 A JP 2003585719A JP 4384918 B2 JP4384918 B2 JP 4384918B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- mmol
- alkoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- MYWRFWIOHPWSRV-UHFFFAOYSA-N CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(N(CC2)CCC2NC(CC(F)(F)F)CNc(cccc2)c2N)=O)ccn1)=O Chemical compound CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(N(CC2)CCC2NC(CC(F)(F)F)CNc(cccc2)c2N)=O)ccn1)=O MYWRFWIOHPWSRV-UHFFFAOYSA-N 0.000 description 1
- NRYHYGHRURUTGW-UHFFFAOYSA-N CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(N(CC2)CCC2c([nH]c2c3)nc2ccc3Cl)=O)ccn1)=O Chemical compound CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(N(CC2)CCC2c([nH]c2c3)nc2ccc3Cl)=O)ccn1)=O NRYHYGHRURUTGW-UHFFFAOYSA-N 0.000 description 1
- FLHKAPFHVVDFBD-UHFFFAOYSA-N CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(O)=O)ccn1)=O Chemical compound CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(O)=O)ccn1)=O FLHKAPFHVVDFBD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37373102P | 2002-04-18 | 2002-04-18 | |
| PCT/US2003/011672 WO2003088967A1 (en) | 2002-04-18 | 2003-04-16 | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005529116A JP2005529116A (ja) | 2005-09-29 |
| JP2005529116A5 JP2005529116A5 (https=) | 2006-12-21 |
| JP4384918B2 true JP4384918B2 (ja) | 2009-12-16 |
Family
ID=29251069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585719A Expired - Lifetime JP4384918B2 (ja) | 2002-04-18 | 2003-04-16 | ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1499316B1 (https=) |
| JP (1) | JP4384918B2 (https=) |
| KR (1) | KR100827470B1 (https=) |
| CN (1) | CN100522166C (https=) |
| AR (1) | AR040405A1 (https=) |
| AT (1) | ATE389406T1 (https=) |
| AU (1) | AU2003223627B2 (https=) |
| BR (1) | BR0309348A (https=) |
| CA (1) | CA2481940A1 (https=) |
| CY (1) | CY1110363T1 (https=) |
| DE (1) | DE60319813T2 (https=) |
| DK (1) | DK1499316T3 (https=) |
| EC (1) | ECSP045367A (https=) |
| ES (1) | ES2301791T3 (https=) |
| IL (1) | IL164584A (https=) |
| MX (1) | MXPA04010173A (https=) |
| NO (1) | NO20045002L (https=) |
| NZ (1) | NZ535763A (https=) |
| PE (1) | PE20040684A1 (https=) |
| PL (1) | PL373889A1 (https=) |
| PT (1) | PT1499316E (https=) |
| RU (1) | RU2323935C2 (https=) |
| SI (1) | SI1499316T1 (https=) |
| TW (1) | TW200306183A (https=) |
| WO (1) | WO2003088967A1 (https=) |
| ZA (1) | ZA200407984B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2511970C (en) | 2003-01-14 | 2012-06-26 | Cytokinetics, Inc. | Urea derivatives useful in the treatment of heart failure |
| PL1615909T3 (pl) | 2003-04-23 | 2009-01-30 | Glaxo Group Ltd | Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych |
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
| WO2006038738A1 (ja) * | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| CN101107231A (zh) | 2005-01-21 | 2008-01-16 | 先灵公司 | 用作组胺h3拮抗剂的咪唑和苯并咪唑衍生物 |
| EP1896453B1 (en) * | 2005-06-20 | 2009-12-02 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
| DE602006010870D1 (de) | 2005-06-20 | 2010-01-14 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| JP4860700B2 (ja) * | 2005-09-20 | 2012-01-25 | シェーリング コーポレイション | ヒスタミンＨ３アンタゴニストとして有用な、１−［［１−［（２−アミノ−６−メチル−４−ピリジニル）メチル］−４−フルオロ−４−ピペリジニル］カルボニル］−４−［２−（２−ピリジニル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−３−イル］ピペリジン |
| CN101273026A (zh) | 2005-09-30 | 2008-09-24 | 霍夫曼-拉罗奇有限公司 | 作为mch受体拮抗剂的茚满衍生物 |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| EP1962852B1 (en) | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US20070142369A1 (en) * | 2005-12-21 | 2007-06-21 | Margaret Van Heek | Combination of an H3 antagonist/inverse agonist and an appetite suppressant |
| JP2009521448A (ja) | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンｈ３アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| AU2007204426A1 (en) * | 2006-01-13 | 2007-07-19 | F. Hoffmann-La Roche Ag | Cyclohexyl piperazinyl methanone derivatives and their use as histamine H3 receptor modulators |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| RU2486187C2 (ru) * | 2007-09-11 | 2013-06-27 | Эбботт Лэборетриз | N-ОКСИДЫ ОКТАГИДРО-ПИРРОЛО[3,4-b]ПИРРОЛА |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| DK2519522T3 (en) | 2009-12-30 | 2014-12-08 | Arqule Inc | SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS |
| KR20190015600A (ko) | 2011-06-24 | 2019-02-13 | 아르퀼 인코포레이티드 | 치환된 이미다조피리디닐-아미노피리딘 화합물 |
| US8815854B2 (en) | 2011-06-24 | 2014-08-26 | Arqule, Inc. | Substituted imidazopyridinyl compounds |
| KR101127756B1 (ko) | 2011-09-02 | 2012-03-23 | 한국과학기술원 | Ｇｉｔ１ 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| JP6046646B2 (ja) | 2014-01-10 | 2016-12-21 | 信越化学工業株式会社 | オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法 |
| US10595550B2 (en) * | 2014-01-22 | 2020-03-24 | Vision Pharma, Llc | Therapeutic composition including carbonated solution |
| WO2017035114A1 (en) * | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as cb-1 inverse agonists |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD290192A5 (de) * | 1986-11-13 | 1991-05-23 | Eisai Co. Ltd,Jp | Pyridinderivat mit antiulzeroeser wirkung |
| ES2048109B1 (es) * | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| ATE174908T1 (de) * | 1993-05-26 | 1999-01-15 | Sumitomo Pharma | Chinazolinonderivate |
| US6211199B1 (en) * | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| PT888336E (pt) * | 1996-02-21 | 2002-12-31 | Aventis Pharma Inc | Novas n-metil-n-(4-(4-(1h-benzimidazol-2-il-amino)-piperidina-1-il)-2-(aril)-butil)-benzamidas substituidas uteis para o tratamento de doencas alergicas |
| AU730650B2 (en) * | 1997-05-01 | 2001-03-08 | Nissan Chemical Industries Ltd. | Benzimidazole derivative |
| US6133291A (en) * | 1998-10-16 | 2000-10-17 | Schering Corporation | N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists |
| AR030946A1 (es) * | 2000-09-20 | 2003-09-03 | Schering Corp | Derivados de imidazoles sustituidos un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos como agonistas o antagonistas duales de h1 y h3 de histamina |
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| NZ535764A (en) * | 2002-04-18 | 2007-10-26 | Schering Corp | 1-(4-piperidinyl) benzimidazolones as histamine H3 antagonists |
-
2003
- 2003-04-16 PT PT03719766T patent/PT1499316E/pt unknown
- 2003-04-16 CA CA002481940A patent/CA2481940A1/en not_active Abandoned
- 2003-04-16 AT AT03719766T patent/ATE389406T1/de not_active IP Right Cessation
- 2003-04-16 KR KR1020047016508A patent/KR100827470B1/ko not_active Expired - Fee Related
- 2003-04-16 NZ NZ535763A patent/NZ535763A/en not_active IP Right Cessation
- 2003-04-16 CN CNB038137798A patent/CN100522166C/zh not_active Expired - Fee Related
- 2003-04-16 WO PCT/US2003/011672 patent/WO2003088967A1/en not_active Ceased
- 2003-04-16 AU AU2003223627A patent/AU2003223627B2/en not_active Ceased
- 2003-04-16 AR AR20030101340A patent/AR040405A1/es active IP Right Grant
- 2003-04-16 ES ES03719766T patent/ES2301791T3/es not_active Expired - Lifetime
- 2003-04-16 BR BR0309348-4A patent/BR0309348A/pt not_active IP Right Cessation
- 2003-04-16 EP EP03719766A patent/EP1499316B1/en not_active Expired - Lifetime
- 2003-04-16 PE PE2003000390A patent/PE20040684A1/es not_active Application Discontinuation
- 2003-04-16 PL PL03373889A patent/PL373889A1/xx not_active Application Discontinuation
- 2003-04-16 MX MXPA04010173A patent/MXPA04010173A/es active IP Right Grant
- 2003-04-16 DK DK03719766T patent/DK1499316T3/da active
- 2003-04-16 RU RU2004133764/04A patent/RU2323935C2/ru not_active IP Right Cessation
- 2003-04-16 JP JP2003585719A patent/JP4384918B2/ja not_active Expired - Lifetime
- 2003-04-16 SI SI200331201T patent/SI1499316T1/sl unknown
- 2003-04-16 DE DE60319813T patent/DE60319813T2/de not_active Expired - Lifetime
- 2003-04-17 TW TW092108912A patent/TW200306183A/zh unknown
-
2004
- 2004-10-04 ZA ZA200407984A patent/ZA200407984B/xx unknown
- 2004-10-14 IL IL164584A patent/IL164584A/en not_active IP Right Cessation
- 2004-10-15 EC EC2004005367A patent/ECSP045367A/es unknown
- 2004-11-17 NO NO20045002A patent/NO20045002L/no unknown
-
2008
- 2008-06-09 CY CY20081100604T patent/CY1110363T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4384918B2 (ja) | ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 | |
| US20040097483A1 (en) | Benzimidazole derivatives useful as histamine H3 antagonists | |
| JP4563800B2 (ja) | ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン | |
| JP4326468B2 (ja) | ヒスタミンｈ３アンタゴニストとして有用なインドール誘導体 | |
| JP4093859B2 (ja) | 抗アレルギー剤としてのピペリジン化合物 | |
| EP1313733A1 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
| EP0925299B1 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
| JP2007533735A (ja) | ケモカイン受容体ｃｃｒ５のモジュレーターとしてのピペリジン誘導体 | |
| TW202527993A (zh) | 雙功能雄激素受體化合物 | |
| AU733034B2 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
| HK1067981B (en) | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20081001 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081222 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090915 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090928 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121002 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |